Monoclonal antibody-based therapies existed great promise in MM.43Recently, tabalumab (LY2127399), with neutralizing activity against BAFF, was found to be well tolerated and showed a better response when combined with bort in relapsed and refractory patients with MM.13 Indeed there are other molecules such as APRIL, BAFF-R,BCMA, and TACI related to BAFF signaling pathway, and particularly APRIL is evidenced playing significant role in MM cell survival and targeting BCMA is in development. Here, TNFSF13B is linked to Miyoshi myopathy.